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Abstract We have characterized a stable and functional trans- 
fectant of the rabbit prolactin receptor in Chinese hamster ovary 
cells, and investigated the action of prolactin (PRL) on the growth 
and differentiation of this transfectant (clone E32). PRL induced 
a significant inhibition of E32 cell proliferation. Growth inhibition 
correlated with gene induction of the molecular marker of ovarian 
differentiation cholesterol side chain cleavage P450 (P45OJ. 
Both effects were inversely proportional to cell confluence. The 
limits and potential development of such transfected cellular sys- 
tems are discussed. 
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1. Introduction 
Prolactin is a pituitary hormone eliciting numerous effects in 
vivo [l]. In mammary gland, PRL is responsible, along with 
insulin and glucocorticoids, for milk protein gene expression 
[2]. In the gonads, PRL stimulates steroidogenesis and growth 
of ovarian follicles [ 11. The role of PRL on cell proliferation has 
also been studied using lymphocyte-derived cell lines [3]. Previ- 
ously, we have shown that mammary gland explants could be 
used to study the effects of PRL on milk protein gene expres- 
sion [4]. We have also shown that CHO cells co-transfected with 
rabbit prolactin receptor (rbPRL-R) cDNA and with a plasmid 
bearing a P-lactoglobulin promoter upstream from the chlo- 
ramphenicol acetyl transferase (CAT) gene, respond to PRL by 
increased CAT activity [5], which is reminiscent of the differen- 
tiation action of PRL obtained either in vivo or with mammary 
explants. In 3T3-F442A pre-adipocytes, growth hormone (GH) 
exhibits anti-mitogenic activity and induces these cells to differ- 
entiate to adipocytes [6,7]. By contrast, CHO cells transfected 
with growth hormone receptor (GH-R) cDNA proliferate in 
response to GH [8]. Thus, it seems that, depending on the tissue, 
GH and PRL, the receptors of which belong to the same super- 
family of cytokine receptors [l], can either promote differentia- 
tion or induce proliferation of a given cell type. Therefore, in 
the present work we have selected and characterized a stable 
rbPRL-R transfectant in CHO cells and investigated the action 
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of PRL on the proliferation/differentiation of this clone, to 
determine to what extent transfection of rbPRL-R would allow 
us to observe the same effects as those already seen in mam- 
mary cells. 
2. Materials and methods 
2.1. Materials 
Bovine P450,, cDNA was kindly provided by Dr. Evan R. Simpson 
[9]. oPRL was a gift of the National Pituitary Agency, USA. 
2.2. CAT assay 
CAT assay has already been described [lo] 
2.3. Microsome preparation and binding assays 
After rinsing with PBS, confluent cells were scrapped off the dish into 
1 ml of 25 mM Tris, pH 7.4, 5 mM EDTA, 10 mM MgCI, and pelleted. 
Cells were resuspended in 0.5 ml of 25 mM Tris, pH 7.4, 10 mM MgCI,, 
sonicated and the lysate used directly for binding studies. For assay, 200 
pg of microsomes were made up in a final volume of 0.5 ml of 25 mM 
Tris, pH 7.4, 10 mM MgCl,, 0.1% BSA (TMBA) and incubated over- 
night at room temperature in the presence of 5 x lo4 cpm ‘251-labeled 
oPRL (specific activity =50 &i/pg) with or without unlabled oPRL 
standards of appropriate concentration. Binding was determined by 
addine 3 ml TMBA followed bv centrifueation for 15 min at 3000 x P. 
Pellet-radioactivity was counted in an LI?B scintillation spectrometer. 
For Scatchard analysis, data were processed with a regression analysis 
package, and results expressed as fmol/mg proteins. 
2.4. Cell proliferation assay 
E32 cells were starved for 5 h in GC3 medium containing 50 ng/ml 
insulin. This step eliminates traces of PRL-like activity in the culture 
medium and makes cells more responsive to PRL. In addition, insulin 
concentration was lowered in this experiment (normally 3 &ml) be- 
cause it enhances cell proliferation (not shown). Cells were then incu- 
bated in the absence or presence of 2 x lo-’ M (400 ng/ml) oPRL for 
24 h in the same medium, and then labeled for 2 h in RPM1 containing 
1.5 @i/ml [3H]thymidine (Amersham, UK). After rinsing with PBS, the 
incorporated radioactivity was determined by scintillation counting. 
2.5. Northern blots 
Northern blotting and quantitation of mRNA expression were per- 
formed as described [l 11, except that 20pg/lane of total RNA were used 
instead of poly(A). In brief, blots were first hybridized with P450,,, 
cDNA [9], then stripped and re-probed for /3-actin transcript. The 
resulting two autoradiograghs were scanned with a Pharmacia LKB 
ImageMaster DTS, and results were expressed in arbitrary units as the 
intensity ratio of the P450,,, band to theg-actin band of the same track. 
2.6. Western blots 
After rinsing with PBS, 8 x lo6 confluent cells were scraped with a 
rubber policeman in 1 ml PBS per 10 cm diam. dish, and pelleted at 
room temperature in a single microtube for 5 min at 5000 rpm. The cell 
pellet was either boiled in reducing sample buffer, or lysed for 30 min 
at 4°C on a rotating wheel in 1 ml of 20 mM Tris, pH 8,137 mM NaCl, 
2.7 mM KCI. 1% NP40. 10% elvcerol, 1 mM PMSF. 5 &ml each 
leupeptin, pepstatin, and aprotinyi. In the latter case, insoluble material 
was removed by centrifugation for 10 min at 15,000 rpm in a cold 
microfuge, and solubilized proteins of the supernatant were im- 
munoprecipitated with the indicated antibodies and protein A-Sepha- 
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rme (Sigma). Total or immunoprecipitated proteins were resolved by 
SDS-PAGE, and electro-transferred onto nitrocellulose. Blots were 
revealed with anti-rbPRL-R polyclonal antibody 46 [12], alcaline phos- 
phatase-linked second Ab and NBT/BCIP dye. For metabolic labeling, 
8 x lo6 cells were incubated at 37°C in a damp atmosphere and 5% COz, 
for 20 min in methionine- and cysteine-deprived DMEM, then for 2 h 
in 5 ml of the same buffer supplemented with 0.5 mCi Tran?+label 
(ICN), and processed as above. Immunoprecipitated labeled proteins 
were separated by SDS-PAGE and revealed by autoradiography. 
whether E3 was a pure clone or a heterogenous population, E3 
cells were diluted and each independent subclone obtained 
from a single cell was tested for [?]oPRL binding, as described 
in section 2. Among 10 randomly chosen subclones, only 3 
displayed significant binding properties over that of parental 
E3 (not shown). Subclone E32 was retained for its highest 
binding capacity and used in subsequent experiments. 
3. Results 
3.1. Characterization of‘prolactin receptor in stably tram&ted 
CHO cells 
In a previous paper we described the isolation of E3, a stable 
CHO cell transfectant of the rbPRL-R [5]. In order to check 
Scatchard analysis indicated that E32 cells contained about 
9000 binding sites per cell, with a K, = 10.8 nM_’ for oPRL 
(Fig. 11). The capability of the receptor to transduce the PRL 
signal was investigated by transfecting E32 cells with an eukar- 
yotic expression vector containing 4 kb of the ovine j?-lacto- 
globulin promoter upstream of the CAT gene [5]. As illustrated 
in Fig. 1 II, addition of 400 ng/ml oPRL to the culture medium 
for 72 h induced a 3-fold increase of CAT activity compared 
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Fig. 1. Characterization of rabbit prolactin receptor in stably transfected CHO cells. (I) Displacement curve by unlabled oPRL of [“‘I]oPRL binding 
to E32 cell microsomes. Inset: Scatchard plot of competition assay, 9000 binding sites/cell, K, = 10.8 nM_‘. (II) Functional test of the rbPRL-R 
expressed by E32 cells (see section 3 and [lo] for details). CAT activity present in E32 cells before (hatched bar) and after (grey bar) addition of 400 
ng/ml oPRL for 72 h. Data are expressed as the ratio of CAT mU to /3-galactosidase (B-gal) U to normalize the results for transfection efficiency 
[lo]. (III) Estimated size of rbPRL-R expressed by E32 cells. E32 (or untransfected CHO Kl) cells were either boiled in reducing sample buffer (A), 
or lysed in 1% NP40 in the presence of protease inhibitors (B-D). In the latter case, solubilized proteins were immunoprecipitated by either 
anti-rbPRL-R polyclonal antibody (pAb) 46 (B,D), or anti-rbPRL-R monoclonal antibody Ml 10 [I21 (C). Total (A) or immunoprecipitated (B,C) 
proteins were resolved by SDS-PAGE and electro-transferred onto nitrocellulose. Blots were revealed as described in section 2. Specificity was 
demonstrated by use of pre-immune serum 42 (A, pAb42). In D, E32 (or untransfected CHO Kl) cells were metabolically labeled and processed as 
described in section 2. The position of molecular weight markers and of the receptor are indicated by numbers on the left and arrows on the right 
of each blot, respectively. 
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to that of non-stimulated cells. Thus, rbPRL-R expressed by 
E32 cells was able to transduce the prolactin signal to a trans- 
fected target gene promoter. 
The size of rbPRL-R expressed in E32 cells was estimated by 
Western blotting with different Ab’s (Fig. 1111, A-C). In all 
cases, a single species was detected at 901100 kDa that often 
migated as a doublet. Since rbPRL-R purified from mammary 
gland was shown to migrate as a 42 kDa species under reducing 
conditions [14], we wondered whether that species would also 
be present in E32 cells but be hidden on blots by Ig heavy 
chains. To clarify this point, we metabolically labeled E32 cells 
and revealed immunoprecipitated bands by direct autoradi- 
ography (Fig. 1111, D). Here again, only the doublet migrating 
at 100 kDa was visible. 
3.2. PRL partially inhibits E32 cell growth and promotes 
differentiation 
In a former paper, we showed that oPRL markedly stimu- 
lated /3-casein synthesis, but had only a slight positive effect on 
[3H]thymidine incorporation by rabbit mammary gland ex- 
plants [4]. Since E32 cells were able to transduce the prolactin 
signal to a transfected target gene promoter (Fig. III), we won- 
dered whether their proliferation would also be stimulated by 
PRL. 
The effect of oPRL on [3H]thymidine incorporation by E32 
cells was investigated as described in section 2. Unexpectedly, 
oPRL partially inhibited E32 cell proliferation, and this effect 
was inversely proportional to cell confluence (36% inhibition 
at 15% confluence, 27% inhibition at 30% confluence) (Fig. 
2A). At 100% confluence, no effect of oPRL was detected, 
probably because of spontaneous cell growth arrest by contact 
inhibition (not shown). 
This result prompted us to speculate that oPRL could poten- 
tially promote differentiation of E32 cells. Our first attempt to 
detect morphological changes by electron microscopy examina- 
tion induced by oPRL was not conclusive (not illustrated). In 
a second trial, we looked for molecular markers of differentia- 
tion. Parental CHO Kl cells originate from an ovary biopsy. 
The differentiation process of granulosa cells is marked by the 
onset of steroidogenic enzyme expression, the first of which is 
cholesterol side chain cleavage P450 (P450,,) [15]. Therefore, 
we followed the expression of P450,,, mRNA in E32 cells after 
stimulation by oPRL. Fig. 2B shows the induction of the en- 
dogenous P450,, gene after addition of 400 @ml oPRL. As 
was the case for growth inhibition, this induction was inversely 
proportional to cell confluence, but some stimulation still ex- 
isted at 100% confluence (not shown). Finally, unlike CHO cells 
stably transfected with GH-R cDNA [16], E32 cells did not 
undergo variation in total protein synthesis under the action of 
oPRL (not shown). 
4. Discussion 
Biochemical and functional characterization of rabbit pro- 
lactin receptor was undertaken in the present study by trans- 
fecting CHO cells with full length rbPRL-R cDNA. Although 
histologically unrelated to rabbit mammary gland from which 
the transfected receptor was cloned, that cellular system proved 
functional in terms of oPRL stimulation of transfected milk 
protein target gene, and thus reproduced the result that we had 
obtained with rabbit mammary gland explants [4]. The differ- 
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Fig. 2. (A) Effect of oPRL on [3H]thymidine uptake by E32 cells. The 
experiments were carried out as described in section 2. Cells were seeded 
so as to reach the indicated confluences at the time of oPRL addition. 
Results are expressed as the mean f S.E.M. of two triplicate experi- 
ments. (B) P45&, mRNA induction by oPRL in E32 cehs. Total RNA 
of unstimulated. or oPRL-stimulated E32 cells at the indicated conflu- 
ences was processed as described in section 2. Results of a representa- 
tive experiment are displayed and expressed as mean + SD. of a trip- 
licate assav. Corresuondine autoradiography of P450, mRNA is 
shown below. The two loadings in each point correspond-to two inde- 
pendant culture plates. 
ence between explants and CHO cells can be reduced to the 
action of oPRL on cell growth. 
The existence of subclones with binding capabilities very 
different from that of the first isolated stable transfectant E3 
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[5] is indicative of either an originally heterogenous population, 
or a progressive shift undergone by E3, with receptor-produc- 
ing cells progressively losing their capacity to express this pro- 
tein. The selected clone E32 encodes about 9000 receptors per 
cell with a K, = 10.8 nM_‘, which is higher than the value found 
for E3 (2.8 nM-’ [17]) and for rabbit mammary gland (2.5-3.2 
nM-’ [ 181). This amount of receptor probably explains the clear 
band seen on Western blots at 100 kDa (Fig. 1111). By contrast, 
this was not possible in transient transfection of CHO cells, 
detection of a band requiring the use of Cos cells to obtain 
sufficient expression [17]. In this respect, receptor size in CHO 
cells is in agreement with the 88 kDa form expressed by Cos 
cells [17], the 103 kDa expressed by BAF-3 cells [19], and the 
94 kDa produced in a baculovirus expression system [20], all 
of them using the same cDNA. Interestingly, we have found the 
same single size receptor in rabbit mammary gland [21]. The 
above data suggest that (i) at least part of the 42 kDa form 
previously described in mammary gland [ 141 might result from 
artefactual proteolytic cleavage of the 100 kDa species, (ii) the 
same 100 kDa protein is the only one encoded both by mam- 
mary gland and transfected cell lines, although a single cDNA 
species was used in the latter case whereas four transcripts are 
present in the former. This confirms our previous observation 
that all rbPRL-R mRNAs contain the same open reading 
frame, and differ only by untranslated regions [22]. 
Although oPRL had the same effect on milk protein gene 
stimulation in mammary explants [4] and CHO cells expressing 
rbPRL-R (this study), it had the opposite action on cell prolif- 
eration. However, this difference must be considered with cau- 
tion. Quantitatively, the principal action of oPRL on explants 
was on /I-casein synthesis, stimulation of [3H]thymidine incor- 
poration being a side effect which could be explained (at least 
in part) by the fact that explants are multicellular structures 
made of different cell types, and hence are much less amenable 
to synchronization by serum starvation than are monolayers of 
homogenous populations of cells such as E32. 
During pregnancy, PRL is part of the endocrine complex 
positively controling the growth of mammary gland [2]. In NB2 
lymphoma cells, which express an internally truncated form of 
PRL-R, oPRL has a proliferative effect [3]. The same is true 
for BAF-3 cells transfected with full-length rbPRL-R [19], and 
for murine FDC-PI cells transfected with the long form of 
human PRL-R [23]. Thus, as far as we know, the stably trans- 
fected CHO cell system described here is the first example in 
which PRL is growth-inhibitory. In addition, this growth inhi- 
bition paralleled the induction of a molecular marker of follicle 
differentiation, making E32 cells as a potential tool for studying 
ovarian steroidogenesis, as P450,,, is the first enzyme of the 
steroidogenesis cascade. 
At present. we do not know if the association of growth 
inhibition, differentiation and PRL signaling to milk protein 
target promoter, concerns CHO cells only or also applies to 
mammary gland. It is, however, striking that the same receptor 
(rbPRL-R) is able to sustain proliferation of a pro-B lymphoid 
BAF-3 cell stable transfectant [ 191, and to inhibit proliferation 
of a CHO cell stable transfectant. This suggests a decisive role 
of the cellular environment, defined by the tissue type in which 
a given receptor is expressed, on how this receptor will act on 
cell growth after stimulation by its cognate ligand. 
A large amount of work published on signal transduction 
through receptors of the super-family of cytokine receptors, 
which encompasses interleukins [24]. interferons [25], growth 
hormone [26], prolactin [27], erythropoietin [28], and LIF/ 
CNTF/OM [29], has provided evidence that non-receptor tyro- 
sine kinases of the Jak family (Jakl, Jak2, or Tyk2) are always 
involved in the very first steps of this process. In the case of 
stable transfectants of PRL-R, all these studies have been per- 
formed in blood cell-derived cell lines. For instance, Jak2 asso- 
ciation with the long or intermediate form of PRL-R, and 
activation by oPRL have been demonstrated in pro-B lymphoid 
BAF-3 cells [19], and in NB2 cells [27], respectively. Since the 
data presented herein suggest a crucial role of the host cell, we 
are currently investigating the role of Jak kinases in PRL signal 
transduction to the p-lactoglobulin gene promoter in E32 cells. 
The next step will be to set up a stable rbPRL-R transfectant 
of the HCl 1 mouse mammary cell line [30] so as to work on 
endogenous milk protein genes, because it is more closely re- 
lated to mammary tissue than are BAF-3 or NB2 cell lines. In 
HCl 1 cellular system, which is even more ‘tissue-specific’ than 
CHO cells with respect to the transfected receptor and target 
gene, will be investigated for the action of oPRL on cell prolif- 
eration and differentiation, to test whether the effects described 
here were restricted to an ovarian-derived cell line or also apply 
to a mammary-derived cell line. 
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